Article
Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.
The oncologist - 6 May 2022
Ravi Praful, Ravi Arvind, Riaz Irbaz B, Freeman Dory, Curran Catherine, Mantia Charlene, McGregor Bradley A, Kilbridge Kerry L, Pan Chong-Xian, Pek Michelle, Choudhury Yukti, Tan Min-Han, Sonpavde Guru P
Abstract excerpt
Serial evaluation of circulating tumor DNA may allow noninvasive assessment of drivers of resistance to immune checkpoint inhibitors (ICIs) in advanced urothelial cancer (aUC). We used a novel, amplicon-based next-generation sequencing assay to identify genomic alterations (GAs) pre- and post-therapy in 39 patients with aUC receiving ICI and 6 receiving platinum-based chemotherapy (PBC). One or more GA was seen...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.